Research letter
Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients

https://doi.org/10.1016/j.jaad.2017.10.043Get rights and content

First page preview

First page preview
Click to open first page preview

References (5)

There are more references available in the full text version of this article.

Cited by (0)

Funding sources: Dr Liu received funding support from the Yale University Medical Student Research Fellowship. Dr King received funding support from The Ranjini and Ajay Poddar Resource Fund for Dermatologic Diseases Research.

Conflicts of interest: Dr King has served on advisory boards or as consultant for Aclaris Therapeutics Inc, Celgene, Concert Pharmaceuticals Inc, Eli Lilly and Company, Pfizer Inc, Regeneron Pharmaceuticals, and Roivant Sciences Ltd. Other authors have no conflicts of interest to report.

View full text